a solar and wind farm with a gap in the middle leading to a tree

How 5 Organisations are Accelerating Sustainability in Pharma

Sustainability in pharma is reshaping the industry as we know it.

Following the UN’s climate summit in 2021, 80% of the world’s largest pharmaceutical organisations have set clear targets to drive environmentally friendly development, manufacture, and distribution of pharmaceutical products. 

Government funded health organisations are taking action too. In the UK, the NHS are working to restructure and future-proof their supply chain by ensuring they only work with sustainable companies. 

Despite the influx of environmental commitments and the overall growing demand for green pharma, it’s critical to remember that not all companies are prioritising initiatives in the same way. 

Recent research reveals huge variabilities in environmental transparency and performance in the pharmaceutical industry, with some organisations producing 5x more emissions than others. 

Read on for more about:

  • The importance of sustainability in pharma
  • 5 leaders of sustainability in pharma
  • Finding your next role in a sustainable organisation


The importance of sustainability in pharma

While the pharmaceutical industry is often self-assessed as ‘medium-impact’, recent research reveals that carbon and environmental performance, and transparency varies between organisations with some heavily outperforming others.  

Despite  this variability, the results show that  the total pharmaceutical industry  is more carbon-intensive and produces more emissions than the automotive industry. 

Critical drivers of environmental damage include:

  • Carbon emissions from drug manufacturing, logistics, as well as the production of power in drug manufacturing and building
  • Active pharmaceutical ingredients (of which resist metabolic degradation) causing water pollution
  • Hazardous substance generation in drug development 


5 leaders of sustainability in pharma

Our short-list of organisations paving the way forward in pharmaceutical sustainability includes those recognised by the ABPI, and those with clear strategies in place that align with UN’s COP26 climate summit commitments. 

1. GlaxoSmithKline

GlaxoSmithKline (GSK) is a principal partner of COP26 and provides expertise, commitment, and action to proactively address climate change. 

This includes working with other organisations across life sciences in a collaborative effort to improve supply chain emissions in wider healthcare, through the promotion and development of  lower-carbon medical treatments, and  new sustainable models of care.

In November 2020, GSK detailed a comprehensive new set of environmental sustainability goals which will see the organisation achieving carbon  net-zero, and nature net positive by 2030. 

These goals include:

  • A 20-year power purchase agreement from solar and wind farms for its Scotland manufacturing site, which currently drives 40% of UK CO2 emissions from manufacturing
  • Funding for low-emission metered dose asthma inhalers, which if successful, could cut emissions from inhalers in the industry by 90%
  • Investing in restoration projects to balance any impact that can’t be reduced
  • Achieving net positive biodiversity at all manufacturing sites

2. Takeda

Takeda has committed to achieving net-zero by 2040 and  has already made significant headway with a 51% decrease in greenhouse gas emissions since 2016. 

Areas targeted for sustainability include streamlining supply chains and reducing distribution networks. So far, supply chain and distribution changes have enabled Takeda to save the same amount of energy it would take to power 3,131 houses for an entire year. Takeda’s initiatives have also increased truckload fill from 60% to 85%, enabling the organisation to take 250 trucks off the road to curb pollution.

Other sustainability initiatives include:

  • Green chemistry to create more environmentally sustainable manufacturing processes for molecules
  • Strategy to drive a 5% reduction in water consumption by 2025

3. NovoNordisk

NovoNordisk, diabetes, obesity and chronic disease specialists, aim to reduce their environmental impact to zero by 2030

This ambition will see a complete transformation in materials used across discovery, development, manufacture, and distribution including plastics, energy, water, waste, and carbon.

NovoNordisk currently  runs all production on renewable energy and  is negotiating with supply chain partners to establish a commitment to switch to renewable energy by 2030.

NovoNordisk’s strategy also includes a pen-recycling initiative that enables pre-filled injector pen users in the UK to recycle the plastics in the pen into items including chairs, and lamps to reduce the number of pens that end up in less sustainable waste management systems. 

4. AstraZeneca

AstraZeneca has committed to reaching net-zero  greenhouse gas emissions across their value chains by 2045 with the Science-Based Targets Initiative. 

AstraZeneca’s strategy includes:

  • Fuel and energy related activity and leased assets emission reduction
  • Upstream transportation and distribution reduction
  • Operational waste reduction
  • Business travel and employee commuting reduction
  • End-of-life treatment of sold products improvements
  • Supply chain renegotiations to ensure that suppliers have science-based targets

5. Amgen

Amgen has invested £200 million into their environmental strategy where they hope to achieve carbon neutrality, reduce water use by 40% and reduce total disposed waste by 75% by 2027. 

Amgen’s environmental sustainability plan includes

  • Adopting biomanufacturing technology to reduce carbon emissions
  • Integrating on-site renewable energy sources
  • Improving sustainability in research and process development
  • Optimising sustainability in manufacturing, transportation, and distribution
  • Engaging with suppliers to assist and encourage carbon reductions
  • Investing in sustainability projects to offset unchangeable emissions

Finding your next role in a sustainable organisation

SRG Talent works alongside organisations across the pharmaceutical industry to place talented scientific and clinical experts in rewarding careers. We work with leading global organisations that are driving the future of sustainability and innovation in pharma.

Click here to find your next role in the pharmaceutical industry.

About the author: Behruz Sheikh specialises in providing innovative solutions around talent to companies across the life sciences sector, with a strong focus on pharmaceuticals, medtech and biotech. Having established a strong network across the North of England across SMEs, start ups, and big pharma, he has provided a wide range of bespoke talent solutions to organisations from ad-hoc niche scientific searches to on-site RPO solutions.  Behruz’s team specialise in placing a wide range of STEM roles spanning across bench to boardroom; typical roles include: Analytical Chemists, Microbiologists, Molecular Biologists, Formulation Chemists, Upstream Biotechnologist, Downstream Biotechnologist, GMP Quality Specialists up to Qualified Person, and commercial roles such as Project Managers and Business Development Managers.

Connect with Behruz on LinkedIn to learn more about our opportunities in the field.

Other articles you may be interested in:

  1. Pharmaceutical Careers: How to Choose a Role
  2. How to Overcome the Top 4 Pharma Supply Chain Challenges
  3. Trends in Biopharma: How and Why The Industry is Changing

blue and white pills spill onto a blue background, the text reads srg, how to prepare your workforce for the future of pharma an SRG guide
How to Prepare your Workforce for the Future of Pharma

Download SRG's latest guide to the global trends, challenges and opportunities shaping the future of talent in the pharmaceutical industry today.


Share location?

Do you want to share your location for better user experience ?